As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.
The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.
The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Democratic leaders in the House and Senate appear to have reached a compromise on a relatively modest plan for controlling prices on certain prescription drugs.
Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations.
Legislative proposals for curbing outlays on prescription drugs have moved to center stage, as Congress looks hard for ways to pay for costly initiatives to repair the nation’s infrastructure, offset global warming and expand health care programs.
The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden.
A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients.
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.
The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.
We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.
How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.
With Democrats controlling Congress and the White House, expectations are high that policy makers will revise certain coverage and payment policies. Jill Wechsler reports.
How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.
How technology can maximize use of manufacturer copay and patient assistance programs.
The second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Ira Studin takes a look at how pharma manufacturers can address extreme pricing and build legitimacy into commercialization to avoid an industry-wide crisis.
Efforts to address prescription drug pricing have expanded. Rick Kelly reports.
Even advocates of U.S. drug pricing reform recognize that President Trump's revised initiative to reduce the price of prescription drugs is unlikely to save money for consumers or the government.
